These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38800869)

  • 1. The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults.
    Mills JA; Mendez E; Strawn JR
    J Child Adolesc Psychopharmacol; 2024 Sep; 34(7):302-309. PubMed ID: 38800869
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact of Antidepressant Dose and Class on Treatment Response in Pediatric Anxiety Disorders: A Meta-Analysis.
    Strawn JR; Mills JA; Sauley BA; Welge JA
    J Am Acad Child Adolesc Psychiatry; 2018 Apr; 57(4):235-244.e2. PubMed ID: 29588049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
    Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
    CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis.
    Mills JA; Strawn JR
    J Am Acad Child Adolesc Psychiatry; 2020 Nov; 59(11):1240-1251. PubMed ID: 31682918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders.
    Jakubovski E; Johnson JA; Nasir M; Müller-Vahl K; Bloch MH
    Depress Anxiety; 2019 Mar; 36(3):198-212. PubMed ID: 30479005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRI) for children and adolescents with anxiety disorders: a systematic review and meta-analysis.
    Stefánsdóttir ÍH; Ivarsson T; Skarphedinsson G
    Nord J Psychiatry; 2023 Feb; 77(2):137-146. PubMed ID: 35587815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents.
    Strawn JR; Mills JA; Poweleit EA; Ramsey LB; Croarkin PE
    Pharmacotherapy; 2023 Jul; 43(7):675-690. PubMed ID: 36651686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
    Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Pharmacotherapy for Pediatric Anxiety Disorders.
    Nicotra CM; Strawn JR
    Child Adolesc Psychiatr Clin N Am; 2023 Jul; 32(3):573-587. PubMed ID: 37201968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Is the Added Benefit of Combining Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Youth with Obsessive Compulsive Disorder? A Bayesian Hierarchical Modeling Meta-Analysis.
    Mendez EM; Dahlsgaard KK; Hjelmgren JM; Mills JA; Suresh V; Strawn JR
    J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):203-211. PubMed ID: 37347947
    [No Abstract]   [Full Text] [Related]  

  • 12. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis.
    Strawn JR; Welge JA; Wehry AM; Keeshin B; Rynn MA
    Depress Anxiety; 2015 Mar; 32(3):149-57. PubMed ID: 25449861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating?
    Ribot R; Ouyang B; Kanner AM
    Epilepsy Behav; 2017 May; 70(Pt A):5-9. PubMed ID: 28407526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
    Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
    BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant class, age, and the risk of deliberate self-harm: a propensity score matched cohort study of SSRI and SNRI users in the USA.
    Miller M; Pate V; Swanson SA; Azrael D; White A; Stürmer T
    CNS Drugs; 2014 Jan; 28(1):79-88. PubMed ID: 24146116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.
    Locher C; Koechlin H; Zion SR; Werner C; Pine DS; Kirsch I; Kessler RC; Kossowsky J
    JAMA Psychiatry; 2017 Oct; 74(10):1011-1020. PubMed ID: 28854296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.